Gland Pharma Limited

rs 25

hip Department Corporate Relationship Department Phiroze Jeejeebhoy Towers Phiroze Jeejeebhoy Towers 25th floor, Dalal Street 25th floor, Dalal Street Mumbai - 400 001 Mumbai - 400 001 Scrip Code: 5432

22%

Y26 FY26 FY25 FY25 Revenue from operations Revenue from operations 17,428 17,428 14,249 14,249 22% 22% 16,954 16,954 3% 3% 64,307 64,307 56,165 56,165 Other Income Other Income Total Income To

3%

enue from operations Revenue from operations 17,428 17,428 14,249 14,249 22% 22% 16,954 16,954 3% 3% 64,307 64,307 56,165 56,165 Other Income Other Income Total Income Total Income Gross Profi

153%

me Other Income Total Income Total Income Gross Profit(1) Gross Profit(1) 1,115 1,115 440 440 153% 153% 632 632 76% 76% 3,163 3,163 2,136 2,136 18,543 18,543 14,689 14,689 11,515 11,515 9,3

76%

l Income Total Income Gross Profit(1) Gross Profit(1) 1,115 1,115 440 440 153% 153% 632 632 76% 76% 3,163 3,163 2,136 2,136 18,543 18,543 14,689 14,689 11,515 11,515 9,370 9,370 26% 26% 2

26%

632 76% 76% 3,163 3,163 2,136 2,136 18,543 18,543 14,689 14,689 11,515 11,515 9,370 9,370 26% 26% 23% 23% 17,585 17,585 11,187 11,187 5% 5% 3% 3% 67,470 67,470 58,301 58,301 41,877 41,8

23%

% 76% 3,163 3,163 2,136 2,136 18,543 18,543 14,689 14,689 11,515 11,515 9,370 9,370 26% 26% 23% 23% 17,585 17,585 11,187 11,187 5% 5% 3% 3% 67,470 67,470 58,301 58,301 41,877 41,877 35,26

5%

18,543 14,689 14,689 11,515 11,515 9,370 9,370 26% 26% 23% 23% 17,585 17,585 11,187 11,187 5% 5% 3% 3% 67,470 67,470 58,301 58,301 41,877 41,877 35,261 35,261 ₹ Mn ?Mn YoY YoY 14% 14%

14%

,187 5% 5% 3% 3% 67,470 67,470 58,301 58,301 41,877 41,877 35,261 35,261 ₹ Mn ?Mn YoY YoY 14% 14% 48% 48% 16% 16% 19% 19% Gross Profit margin (%) Gross Profit margin (%) 66% 66% 66% 66%

48%

5% 3% 3% 67,470 67,470 58,301 58,301 41,877 41,877 35,261 35,261 ₹ Mn ?Mn YoY YoY 14% 14% 48% 48% 16% 16% 19% 19% Gross Profit margin (%) Gross Profit margin (%) 66% 66% 66% 66% 66% 66

16%

67,470 67,470 58,301 58,301 41,877 41,877 35,261 35,261 ₹ Mn ?Mn YoY YoY 14% 14% 48% 48% 16% 16% 19% 19% Gross Profit margin (%) Gross Profit margin (%) 66% 66% 66% 66% 66% 66% 65% 6

19%

67,470 58,301 58,301 41,877 41,877 35,261 35,261 ₹ Mn ?Mn YoY YoY 14% 14% 48% 48% 16% 16% 19% 19% Gross Profit margin (%) Gross Profit margin (%) 66% 66% 66% 66% 66% 66% 65% 65% 63%

“PAT Margin(6) (< Mn / %) (₹ Mn / %) 16,826 16,826 26% 26% 12,689 12,689 23% 23% 3,475 3,475 24% 24% 4,490 4,490 26% 26% 5,244 5,244 30% 30% 1,865 1,865 13% 13% 2,797 2,797 16% 16% 3,667 3,667 21% 21% 10,455 10,455 16% 16% 6,985 6,985 12% 12% Q4 FY25 Q4 FY25 Q3 FY26 Q3 FY26 Q4 FY26 Q4 FY26 FY25 FY25 FY26 FY26 Q4 FY25 Q4 FY25 Q3 FY26 Q3 FY26 Q4 FY26 Q4 FY26 FY25 FY25 FY26 FY26 1.”

“Mn) 41,248 41,248 45,613 45,613 Gross Profit *1> / Gross Profit Margin*2) Gross Profit (1) / Gross Profit Margin(2) (₹ Mn / %) 23,943 23,943 58% 58% 27,662 27,662 61% 61% 10,332 10,332 11,790 11,790 12,648 12,648 6,280 6,280 61% 61% 7,147 7,147 61% 61% 7,800 7,800 62% 62% Q4 FY25 Q4 FY25 Q3 FY26 Q3 FY26 Q4 FY26 Q4 FY26 FY25 FY25 FY26 FY26 Q4 FY25 Q4 FY25 Q3 FY26 Q3 FY26 Q4 FY26 Q4 FY26 FY25 FY25 FY26 FY26 Adj.”

“Mn / %) 17,163 17,163 38% 38% 13,232 3,232 29% 29% 14,451 14,451 35% 35% 10,868 10,868 26% 26% 3,954 3 ) 9 5 4 2,913 2,913 38% 38% 28% 28% 4,342 4 ) 3 4 2 3,274 3,274 37% 28% 28% 5,198 5 ) 1 9 8 4,211 4,211 41% 33% 33% 4 1 % 1,922 1,922 5% 5% 2,230 2,230 5% 5% 503 503 5% 5% 650 650 5% 5% 506 506 4% 4% Q4 FY25 Q4 FY25 Q3 FY26 Q3 FY26 Q4 FY26 Q4 FY26 FY25 FY25 FY26 FY26 Q4 FY25 Q4 FY25 Q3 FY26 Q3 FY26 Q4 FY26 Q4 FY26 FY25 FY25 FY26 FY26 ■ ■ Adj.”

“Mn) (₹ Mn) 87,238 91,507 1,03,580 1,03,580 ROCE(2) / RONW(3) ROCE (2) /RONW (3) (%) (%) —A— RoCE — RoNW RoNW RoCE 11% 11% 9% 9% 9% 9% 8% 8% 12% 12% 11% 11% 15.0% 10.0% 5.0% 0.0% FY24 FY24 FY25 FY25 FY26 FY26 FY24 FY24 FY25 FY25 FY26 FY26 Capital Expenditure Capital Expenditure (?”

“Mn) (₹ Mn) 9,968 9,968 9,147 9,147 10,314 10,314 18,394 1 8 ' 3 9 4 15,197 15,197 25,562 2 5 ’5 6 2 22,870 22,870 FY24 FY24 FY25* FY25* FY26 FY26 FY24 FY24 FY25 FY25 FY26 FY26 .”

“Mn) (₹ Mn) 21,554 21,683 24,855 24,855 Cash Conversion Cycle (CCC)(3)(4) Cash Conversion Cycle (CCC) (3)(4) (# of Days) (# of Days) 173 173 152 152 78 78 -57 -57 FY24 FY24 ■ 172 172 138 138 100 100 -66 -66 FY25 FY25 ■ 164 1 6 4 130 130 97 97 -63 -63 FY26 FY26 ■ FY24 FY24 FY25 FY25 FY26 FY26 Receivable days Receivable days Inventory days Inventory days Payable days Payable days Cash conversion cycle Cash conversion cycle 9 1.”

“9 GLAND Business Update Business Update Base Business (Gland) Updates Base Business (Gland) Updates (cid:127) (cid:127) ; (cid:127) • (cid:127) • (cid:127) • (cid:127) (cid:127) • • (cid:127) • (cid:127) (cid:127) • (cid:127) • (cid:127) • I R&D Expenses: Total R&D expenses were ₹506 million in Q4 FY26, representing 4% of base business revenue.”

“The R&D expenditure R&D Expenses: Total R&D expenses were 506 million in Q4 FY26, representing 4% of base business revenue.”

“During FY26, 31 New Launches: The company launched five molecules in the USA this quarter, including Dalbavancin, Brimonidine etc.”

“During FY26, 31 products were launched in the USA.”

Regd. Office

1

Corporate Office

1

Base business

1

Investor Relations

1

Regd. Office

Survey No. 143-148, 150 & 151, Near Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office

Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLANDI GLAND PHARMA GLAND PHARMA Investor Investor Presentation Presentation Q4 FY26 & FY26 Q4 FY26 & FY26 15 th May 2026 15th May 2026 Safe Harbour Statement Safe Harbour Statement The Presentation is to provide the general background information about the The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor estimates and should not be considered as a recomm

Base business

• Growth seen across some of the key (cid:127) Growth seen across some of the key products including Huminsulin, Rocuronium products including Huminsulin, Rocuronium Bromide etc. Bromide etc. 4,734 4,734 4,606 4,606 1 1 FY25 FY25 FY26 FY26 ICLANDj 17 17 iGiANPl GLAND PHARMA GLAND PHARMA Thank You Thank You

Investor Relations

Sampath Kumar Pallerlamudi Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer Company Secretary & Compliance Officer Shriniwas P. Dange Shriniwas P. Dange Investor Relations Investor Relations investors@glandpharma.com investors@glandpharma.com Corporate Office Corporate Office Gland Pharma Limited Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Pashamylaram (V), Patancheru (M), Sangareddy District Sangareddy District Hyderabad 502307, Telangana, India Hyderabad 502307, Telangana, India 3 S E 543245 543245 0 NSE GLAND GLAND Bloomberg GLAND:IN 3LANDJN 18 18